Verinos Pharma

Executive Summary

Verinos Pharma, a privately held German biotechnology company founded in 2021 and headquartered in Munich, is pioneering novel cancer immunotherapies through its proprietary targeted protein degradation platform. The company specializes in developing small molecule drugs designed to selectively degrade proteins that drive tumor growth and enable immune evasion. By leveraging this innovative approach, Verinos aims to address key limitations of current cancer treatments, potentially offering patients more effective and less toxic therapeutic options. As an early-stage biotech, the company has not yet disclosed its lead programs or financials, but its focus on the emerging field of targeted protein degradation positions it within a highly competitive and rapidly evolving landscape. The company was identified through biopharmguy.com and has limited public information, suggesting it remains in preclinical or early research stages.

Upcoming Catalysts (preview)

• TBDAnnouncement of lead program or preclinical data30% success
• TBDSeries A or seed funding round40% success
• TBDPartnership or collaboration with larger pharma20% success